Literature DB >> 6674240

Serum pyruvate kinase in different neuromuscular diseases and in carriers of muscular dystrophy.

C Savonitto, G Bonadonna, L G Bongiovanni, E Duso, D De Grandis.   

Abstract

Serum pyruvate kinase and creatine kinase activities were measured in a group of patients with various neuromuscular diseases and in carriers of muscular dystrophy. Elevated values of PK were usually but not invariably associated with elevated levels of CK. THe data showed that PK activity was elevated in all patients with DMD, high values generally correlating inversely with age or disease duration. In definite carriers, the level of PK was raised simultaneously with CK, while in potential carriers, classified by their relationship with MD patients in mothers, sisters and other relatives, the PK levels were elevated in 23%, 44% and 10% respectively, indicating especially for sisters, an increased genetic probability of being a definite carrier. In this way, we have confirmed that the serum PK assay is more sensitive in younger subjects and that combined CK and PK measurement will be of value in detecting a higher proportion of potential carriers.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6674240     DOI: 10.1007/bf02125620

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  15 in total

1.  Recommended method for the determination of creatine kinase in blood modified by the inclusion of EDTA. The Committee on Enzymes of the Scandinavian Society for Clinical Chemistry and Clinical Physiology (SCE).

Authors:  M Hørder; E Magid; E Pitkänen; M Härkönen; J H Strömme; L Theodorsen; W Gerhardt; J Waldenström
Journal:  Scand J Clin Lab Invest       Date:  1979-02       Impact factor: 1.713

2.  Serum pyruvate kinase in carriers of Duochenne muscular dystrophy.

Authors:  S Yamuna; K Valmikinathan; D Burt; A E Emery
Journal:  Clin Chim Acta       Date:  1977-08-15       Impact factor: 3.786

3.  Serum enzyme alterations in neuromuscular disorders.

Authors:  T L Munsat; R Baloh; C M Pearson; W Fowler
Journal:  JAMA       Date:  1973-12-24       Impact factor: 56.272

4.  Serum pyruvate kinase in muscle disease and carrier states.

Authors:  M C Alberts; F J Samaha
Journal:  Neurology       Date:  1974-05       Impact factor: 9.910

5.  Pyruvate kinase: diagnostic value in neuromuscular disease.

Authors:  I M Weinstock; J Behrendt; H E Wittshire; J Keleman; S Louis
Journal:  Clin Chim Acta       Date:  1977-11-01       Impact factor: 3.786

6.  The carrier state in muscular dystrophy of the Duchenne type.

Authors:  A T Milhorat; L Goldstone
Journal:  JAMA       Date:  1965-10-11       Impact factor: 56.272

7.  Serum creatine kinase and pyruvate kinase in Duchenne muscular dystrophy carrier detection.

Authors:  M E Percy; L S Chang; E G Murphy; I Oss; C Verellen-Dumoulin; M W Thompson
Journal:  Muscle Nerve       Date:  1979 Sep-Oct       Impact factor: 3.217

8.  Serum pyruvate-kinase (PK) and creatine-phosphokinase (CPK) in progressive muscular dystrophies.

Authors:  M Zatz; L J Shapiro; D S Campion; E Oda; M M Kaback
Journal:  J Neurol Sci       Date:  1978-05       Impact factor: 3.181

9.  Serum pyruvate-kinase (PK) and creatine-phosphokinase (CPK) in female relatives and patients with X-linked muscular dystrophies (Duchenne and Becker).

Authors:  M Zatz; L J Shapiro; D S Campion; M M Kaback; P A Otto
Journal:  J Neurol Sci       Date:  1980-06       Impact factor: 3.181

10.  Variation of serum creatine kinase levels with age in normal females: implications for genetic counselling in Duchenne muscular dystrophy.

Authors:  R J Lane; A D Roses
Journal:  Clin Chim Acta       Date:  1981-06-02       Impact factor: 3.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.